http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 02 Sep 2026 05:11:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+Comments/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html <p>(Updated - September 2, 2026 5:10 AM EDT)</p><p>Canaccord analyst Kyle Mikson initiates coverage on BillionToOne Inc (NASDAQ: BLLN) with a Buy rating and a price target of $120.00.</p><p>The analyst comments "We are initiating coverage of BillionToOne (BLLN) with a BUY rating and a 12-month price target of $120 (~70 pages). We believe BillionToOne’s proprietary smNGS and QCT technologies provide a differentiated and difficult-to-replicate foundation with its UNITY and Northstar portfolios that supports strong competitive positioning across prenatal and oncology diagnostics, respectively. The company has demonstrated exceptional growth while achieving GAAP profitability at a relatively early stage compared to diagnostics peers. http://www.streetinsider.com/Hot+Comments/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html Wed, 02 Sep 2026 05:11:53 -0400 BLLN http://www.streetinsider.com/Hot+New+Coverage/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html <p>(Updated - September 2, 2026 5:10 AM EDT)</p><p>Canaccord analyst Kyle Mikson initiates coverage on BillionToOne Inc (NASDAQ: BLLN) with a Buy rating and a price target of $120.00.</p><p>The analyst comments "We are initiating coverage of BillionToOne (BLLN) with a BUY rating and a 12-month price target of $120 (~70 pages). We believe BillionToOne’s proprietary smNGS and QCT technologies provide a differentiated and difficult-to-replicate foundation with its UNITY and Northstar portfolios that supports strong competitive positioning across prenatal and oncology diagnostics, respectively. The company has demonstrated exceptional growth while achieving GAAP profitability at a relatively early stage compared to diagnostics peers. http://www.streetinsider.com/Hot+New+Coverage/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html Wed, 02 Sep 2026 05:11:53 -0400 BLLN http://www.streetinsider.com/New+Coverage/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html <p>(Updated - September 2, 2026 5:10 AM EDT)</p><p>Canaccord analyst Kyle Mikson initiates coverage on BillionToOne Inc (NASDAQ: BLLN) with a Buy rating and a price target of $120.00.</p><p>The analyst comments "We are initiating coverage of BillionToOne (BLLN) with a BUY rating and a 12-month price target of $120 (~70 pages). We believe BillionToOne’s proprietary smNGS and QCT technologies provide a differentiated and difficult-to-replicate foundation with its UNITY and Northstar portfolios that supports strong competitive positioning across prenatal and oncology diagnostics, respectively. The company has demonstrated exceptional growth while achieving GAAP profitability at a relatively early stage compared to diagnostics peers. http://www.streetinsider.com/New+Coverage/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html Wed, 02 Sep 2026 05:11:53 -0400 BLLN http://www.streetinsider.com/Analyst+Comments/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html <p>(Updated - September 2, 2026 5:10 AM EDT)</p><p>Canaccord analyst Kyle Mikson initiates coverage on BillionToOne Inc (NASDAQ: BLLN) with a Buy rating and a price target of $120.00.</p><p>The analyst comments "We are initiating coverage of BillionToOne (BLLN) with a BUY rating and a 12-month price target of $120 (~70 pages). We believe BillionToOne’s proprietary smNGS and QCT technologies provide a differentiated and difficult-to-replicate foundation with its UNITY and Northstar portfolios that supports strong competitive positioning across prenatal and oncology diagnostics, respectively. The company has demonstrated exceptional growth while achieving GAAP profitability at a relatively early stage compared to diagnostics peers. http://www.streetinsider.com/Analyst+Comments/Canaccord+Starts+BillionToOne+Inc+%28BLLN%29+at+Buy/27014765.html Wed, 02 Sep 2026 05:11:53 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+26++Filed+by%3A+KOLLURI+KRISHNA+KITTU/26998301.html si-local-file:///var/storage/secattach/20260828/26998301.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+26++Filed+by%3A+KOLLURI+KRISHNA+KITTU/26998301.html Fri, 28 Aug 2026 16:21:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+25++Filed+by%3A+ten+Bosch+John+Roderick/26991751.html si-local-file:///var/storage/secattach/20260827/26991751.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+25++Filed+by%3A+ten+Bosch+John+Roderick/26991751.html Thu, 27 Aug 2026 20:20:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+25++Filed+by%3A+Tsao+David/26991752.html si-local-file:///var/storage/secattach/20260827/26991752.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+25++Filed+by%3A+Tsao+David/26991752.html Thu, 27 Aug 2026 20:20:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+Tsao+David/26975034.html si-local-file:///var/storage/secattach/20260825/26975034.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+Tsao+David/26975034.html Tue, 25 Aug 2026 16:22:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+ten+Bosch+John+Roderick/26974774.html si-local-file:///var/storage/secattach/20260825/26974774.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+ten+Bosch+John+Roderick/26974774.html Tue, 25 Aug 2026 16:11:00 -0400 BLLN http://www.streetinsider.com/Press+Releases/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html <div class="xn-content"> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BLLN" idsrc="xmltag.org" >BillionToOne, Inc.</span> (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of <i>A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population</i> in <i><span>The Green Journal</span></i>. This is the first prospective NIPT study http://www.streetinsider.com/Press+Releases/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/PRNewswire/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html <div class="xn-content"> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BLLN" idsrc="xmltag.org" >BillionToOne, Inc.</span> (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of <i>A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population</i> in <i><span>The Green Journal</span></i>. This is the first prospective NIPT study http://www.streetinsider.com/PRNewswire/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/Press+Releases/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html <div class="xn-content"> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BLLN" idsrc="xmltag.org" >BillionToOne, Inc.</span> (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of <i>A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population</i> in <i><span>The Green Journal</span></i>. This is the first prospective NIPT study http://www.streetinsider.com/Press+Releases/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/PRNewswire/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html <div class="xn-content"> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BLLN" idsrc="xmltag.org" >BillionToOne, Inc.</span> (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of <i>A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population</i> in <i><span>The Green Journal</span></i>. This is the first prospective NIPT study http://www.streetinsider.com/PRNewswire/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/Press+Releases/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html <div class="xn-content"> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BLLN" idsrc="xmltag.org" >BillionToOne, Inc.</span> (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of <i>A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population</i> in <i><span>The Green Journal</span></i>. This is the first prospective NIPT study http://www.streetinsider.com/Press+Releases/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/PRNewswire/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html <div class="xn-content"> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.menark" idsrc="xmltag.org" >MENLO PARK, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:BLLN" idsrc="xmltag.org" >BillionToOne, Inc.</span> (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of <i>A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population</i> in <i><span>The Green Journal</span></i>. This is the first prospective NIPT study http://www.streetinsider.com/PRNewswire/Largest+Prospective+Study+in+General-Risk+Pregnancies+Strengthens+Evidence+for+cfDNA+Fetal+Risk+Assessment+as+a+Primary+Screen+for+Recessive+Conditions/26942937.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html <div class="xn-content"> <p>In the news release, Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions, issued <chron>18-Aug-2026</chron> by BillionToOne over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions</h3> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/PRNewswire/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html <div class="xn-content"> <p>In the news release, Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions, issued <chron>18-Aug-2026</chron> by BillionToOne over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions</h3> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible http://www.streetinsider.com/PRNewswire/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html <div class="xn-content"> <p>In the news release, Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions, issued <chron>18-Aug-2026</chron> by BillionToOne over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions</h3> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/PRNewswire/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html <div class="xn-content"> <p>In the news release, Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions, issued <chron>18-Aug-2026</chron> by BillionToOne over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions</h3> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible http://www.streetinsider.com/PRNewswire/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html <div class="xn-content"> <p>In the news release, Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions, issued <chron>18-Aug-2026</chron> by BillionToOne over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions</h3> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/PRNewswire/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html <div class="xn-content"> <p>In the news release, Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions, issued <chron>18-Aug-2026</chron> by BillionToOne over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions</h3> <p class="prntac"><i>Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible http://www.streetinsider.com/PRNewswire/C+O+R+R+E+C+T+I+O+N+--+BillionToOne/26948418.html Tue, 18 Aug 2026 12:08:00 -0400 A.08686595 BLLN O.00160367 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+10++Filed+by%3A+ten+Bosch+John+Roderick/26914718.html si-local-file:///var/storage/secattach/20260812/26914718.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+10++Filed+by%3A+ten+Bosch+John+Roderick/26914718.html Wed, 12 Aug 2026 18:55:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+10++Filed+by%3A+Tsao+David/26914709.html si-local-file:///var/storage/secattach/20260812/26914709.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BillionToOne%2C+Inc.++++++++For%3A+Aug+10++Filed+by%3A+Tsao+David/26914709.html Wed, 12 Aug 2026 18:52:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+ten+Bosch+John+Roderick/26897311.html si-local-file:///var/storage/secattach/20260810/26897311.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+ten+Bosch+John+Roderick/26897311.html Mon, 10 Aug 2026 15:18:00 -0400 BLLN http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+Tsao+David/26897281.html si-local-file:///var/storage/secattach/20260810/26897281.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BillionToOne%2C+Inc.+++++++++++++++++++++Filed+by%3A+Tsao+David/26897281.html Mon, 10 Aug 2026 15:11:00 -0400 BLLN